Cannabinoids May Protect Retinal Neurons in Glaucoma and Diabetic Eye Disease Beyond Just Lowering Eye Pressure
While cannabis is known to lower eye pressure, this review highlights emerging evidence that cannabinoids may also directly protect retinal neurons from death in diseases like glaucoma and diabetic retinopathy.
Quick Facts
What This Study Found
The connection between cannabis and eye health goes back to the early 1970s when smoking cannabis was found to lower intraocular pressure (IOP). But this review argues that lowering IOP alone is not sufficient to prevent vision loss in diseases like glaucoma.
Glaucoma and diabetic retinopathy are increasingly understood as neurodegenerative diseases characterized by ischemia-induced excitotoxicity and loss of retinal neurons. The review presents evidence that cannabinoids, both endogenous and synthetic, have neuroprotective properties that could directly protect retinal cells from death.
This neuroprotective potential goes beyond IOP reduction and suggests cannabinoids could address the underlying neurodegeneration that drives vision loss, potentially representing a new therapeutic strategy for retinal diseases.
Key Numbers
Cannabis has been known to lower IOP since the 1970s. Glaucoma is the second leading cause of blindness globally. Both CB1 and CB2 receptors are present in retinal tissue.
How They Did This
Narrative review of preclinical evidence on the neuroprotective and therapeutic potential of endogenous and synthetic cannabinoids in retinal disease, including glaucoma and diabetic retinopathy.
Why This Research Matters
Glaucoma is the second leading cause of blindness worldwide. If cannabinoids can protect retinal neurons beyond simply lowering eye pressure, they could complement existing treatments and potentially prevent vision loss that current therapies cannot address.
The Bigger Picture
This review reframes the cannabis-glaucoma discussion from a narrow focus on IOP to a broader neuroprotection paradigm. As retinal diseases are increasingly recognized as neurodegenerative conditions, neuroprotective approaches including cannabinoids deserve more clinical investigation.
What This Study Doesn't Tell Us
Most neuroprotection evidence is preclinical. The review does not quantify the degree of neuroprotection or compare it to existing treatments. Systemic cannabinoid delivery for eye disease raises questions about side effects versus local benefit.
Questions This Raises
- ?Could topical cannabinoid formulations deliver neuroprotection directly to the retina?
- ?Would the neuroprotective effects complement existing IOP-lowering treatments?
- ?What cannabinoid formulations would be most suitable for retinal disease?
Trust & Context
- Key Stat:
- Cannabinoids may protect retinal neurons through neuroprotection, not just IOP reduction
- Evidence Grade:
- Narrative review of primarily preclinical evidence. Compelling theoretical framework but limited clinical evidence for neuroprotection.
- Study Age:
- Published in 2016. Research on cannabinoid neuroprotection in retinal diseases has continued to advance.
- Original Title:
- Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.
- Published In:
- Neural plasticity, 2016, 8373020 (2016)
- Authors:
- Kokona, Despina, Georgiou, Panagiota-Christina, Kounenidakis, Mihalis, Kiagiadaki, Foteini, Thermos, Kyriaki
- Database ID:
- RTHC-01198
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Does cannabis help with glaucoma?
Cannabis lowers eye pressure, which is the main risk factor for glaucoma. This review adds that cannabinoids may also directly protect retinal neurons from dying, addressing the underlying neurodegeneration that drives vision loss.
Should glaucoma patients use cannabis?
The neuroprotective evidence is mostly preclinical. While cannabis does lower eye pressure, the short duration of this effect and systemic side effects currently limit its practical use compared to conventional glaucoma medications.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-01198APA
Kokona, Despina; Georgiou, Panagiota-Christina; Kounenidakis, Mihalis; Kiagiadaki, Foteini; Thermos, Kyriaki. (2016). Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.. Neural plasticity, 2016, 8373020. https://doi.org/10.1155/2016/8373020
MLA
Kokona, Despina, et al. "Endogenous and Synthetic Cannabinoids as Therapeutics in Retinal Disease.." Neural plasticity, 2016. https://doi.org/10.1155/2016/8373020
RethinkTHC
RethinkTHC Research Database. "Endogenous and Synthetic Cannabinoids as Therapeutics in Ret..." RTHC-01198. Retrieved from https://rethinkthc.com/research/kokona-2016-endogenous-and-synthetic-cannabinoids
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.